4th Quarter - Report

SLC HEALTH STRATEGIES, LLC for EISAI INC.

Firm
Client
Income
$40,500
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

S 2410 Carl Levin National Defense Authorization Act for Fiscal Year 2015National Defense Authorization Bill for 2015 HR 4435 Howard P. "Buck" McKeon National Defense Authorization Act for Fiscal Year 2015 HR 4870 Department of Defense Appropriations Act, 2015 which was then included in HR 83 - Consolidated and Further Continuing Appropriations Act, 2015 --PL Law No: 113-235 Specifically, DoD/TRICARE coverage of obesity drugs

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4870 (113th), H.R. 4435 (113th), H.R. 83 (113th)

Budget/Appropriations BUD

FY 2014 Omnibus HR 3547 FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67 HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93 H Con Res 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024 HJ Res 124 Continuing Appropriations Resolution, 2015 In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of obesity Rx products HR 83 Consolidated and Further Continuing Appropriations Act, 2015, PL 113-235 which include the FY 15 Department of Defense Appropriations Act, 2015, specifically DoD/TRICARE coverage of obesity drugs

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3547 (113th), H.J.Res. 59 (113th), H.Con.Res. 96 (113th), H.R. 83 (113th), H.J.Res. 124 (113th), H.R. 4302 (113th), H.J.Res. 106 (113th)

Pharmacy PHA

Obesity product matters as well as FDA funding HR 4299 --Improving Regulatory Transparency for New Medical Therapies Act re: DEA scheduling of controlled substances S. 2862 - Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 re: DEA scheduling of controlled substances

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4299 (113th), S. 2862 (113th)

Medicare/Medicaid MMM

FY 2014 Omnibus HR 3547 FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67 HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93 HR 83 - Consolidated and Further Continuing Appropriations Act, 2015 - PL Law No: 113-235 In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets HR 2415/S 1184 - Treat and Reduce Obesity Act of 2013 -- Medicare coverage of obesity medications

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4302 (113th), H.J.Res. 59 (113th), H.R. 83 (113th), H.R. 2415 (113th), H.R. 3547 (113th), H.J.Res. 106 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.